Clinical Trial Details
EORTC-1410
Back to Clinical Trials Database
INTELLANCE 2: ABT 414 alone or ABT 414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group
| Trial Status | All trial activities ended |
|---|---|
| Dates |
Date of activation: 14-Jan-2015 Date Step1 close: 04-Jul-2016 Date Step2 close: 13-Jul-2016 |
| Data management at EORTC | Yes |
| Design |
Phase 2 Randomized open label |
| Targeted Sample size | EORTC Groups: 240 - All Groups: 240 |
| Treatment | |
| Study Staff | |
| Type of cancer | |
| Participating groups | |
| Protocol summary | http://clinicaltrials.gov/study/NCT02343406 |
| NCT number | NCT02343406 |
| EudraCT | 2014-004438-24 |
